Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of atractylenolide-III derivative in preparation of platelet aggregation resisting drug and platelet aggregation resisting drug

An anti-platelet aggregation and atractylide-based technology, applied in the field of medicine, can solve the problems of doctors easily misdiagnosed, missed treatment opportunities, and difficult treatment.

Active Publication Date: 2015-04-08
SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But sometimes there may be no obvious symptoms, such as the common deep vein thrombosis of the lower extremities, only calf soreness and discomfort, many patients think it is fatigue or catch a cold, and do not take it seriously, so it is easy to miss the best time for treatment
It is particularly regrettable that many doctors are prone to misdiagnose this, and when typical lower extremity edema occurs, it will not only bring difficulties to the treatment, but also easily leave sequelae

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of atractylenolide-III derivative in preparation of platelet aggregation resisting drug and platelet aggregation resisting drug
  • Application of atractylenolide-III derivative in preparation of platelet aggregation resisting drug and platelet aggregation resisting drug
  • Application of atractylenolide-III derivative in preparation of platelet aggregation resisting drug and platelet aggregation resisting drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0039] The technical solutions of the present invention will be further described in detail below in conjunction with the examples.

[0040] When both R1 and R2 are methyl, it is Atractylodes lactone III, and its structural formula is

[0041]

[0042] Verify the present invention by concrete pharmaceutical test below:

[0043] 1. Preparation of test materials

[0044] Atractylodes Ⅲ, dissolved in DMSO.

[0045] 2. Experimental verification process

[0046] ① Platelet aggregation test

[0047] ⑴Preparation of platelets: human-sourced high-concentration platelet plasma, prepared platelet count of 3×10 8 / mL, placed in a 37°C water bath.

[0048] (2) Concentration gradient of Atractylodes Ⅲ compound: In 300uL platelets, the final concentrations of the compounds are 0.1 μm, 0.5 μm, 1 μm, 5 μm, 10 μm, respectively.

[0049] Compounds were incubated in platelets for 3 min before the experiment started, and resting and DMSO were set as controls in the experiment. Use thrombi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a platelet aggregation resisting drug. The platelet aggregation resisting drug comprises an atractylenolide-III derivative represented by a structural formula 1 shown in specifications. The invention further relates to application of an atractylenolide-III derivative in preparation of the platelet aggregation resisting drug. The platelet aggregation resisting drug, which is simple in composition and is prepared from effective ingredients of natural medicinal raw materials or effective ingredient extracts of the medicinal raw materials, provided by the invention has a good treatment effect, is free from toxic or side effects, is not prone to the generation of tolerance, is convenient to take and is generally applicable to the problems, such as viscous blood and thrombus, caused by too-high platelet aggregation rate.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the preparation and application of atractyloid III derivatives for anti-platelet aggregation. Background technique [0002] Modern medicine believes that there is a certain relationship between the formation of thrombus and the high rate of platelet aggregation. [0003] Thrombus starts from the local coagulation mechanism. After thrombus formation on the surface of hyperarterial intima, the thrombus is covered by proliferating endothelial cells, and the platelets and white blood cells incorporated into the arterial wall thrombus disintegrate to release lipids and other active substances, gradually forming Atheromatous plaque. The latter believes that the disease begins with increased platelet activating factor (PAF) in the arterial intima, where platelets adhere and then aggregate, followed by fibrin deposition to form microthrombi. After platelet aggregation, some active substances ar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/365A61P7/02A61P9/10
CPCA61K31/365
Inventor 张俊峰刘俊岭陈一竹
Owner SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products